Latest From BeiGene Ltd.
Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.
Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: AbbVie's Skyrizi takes psoriasis lead, Amarin goes it alone, Viatris debuts, BeiGene on US drug pricing and Roche think neuroscience is the new oncology.
Drug Discovery Tools
- Drug Discovery Tools
- In Vitro Diagnostics
- Therapeutic Areas
- BeiGene (Beijing) Co. Ltd.
- Parent & Subsidiaries
- BeiGene Ltd.
- Senior Management
John V Oyler, CEO
Howard Liang, PhD, CFO & Chief Strategy Officer
Guillaume Vignon, PhD, SVP, Bus. Dev.
- Contact Info
Phone: 10 851 48500
No. 30 Science Park Rd. Zhong-Guan-Cun
Life Science Pk
Changping District, 102206
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.